Copyright
©The Author(s) 2018.
World J Clin Cases. Oct 26, 2018; 6(12): 514-520
Published online Oct 26, 2018. doi: 10.12998/wjcc.v6.i12.514
Published online Oct 26, 2018. doi: 10.12998/wjcc.v6.i12.514
Table 2 Eradication rates according to cytochrome P450 2C19 and interleukin-1β genotypes n (%)
| Hybrid therapy | (n = 85) | IL-1β-511 C/C(normal gastric acid)(n = 27) | IL-1β-511 C/T, T/T(low gastric acid)(n = 58) |
| 79/85 (92.94) | 25/27 (92.59) | 54/58 (93.10) | |
| CYP2C19 EM (n = 37) | 33/37 (89.19) | 13/14 (92.86) | 20/23 (86.96) |
| CYP2C19 PM and hetero EM (n = 48) | 46/48 (95.83) | 12/13 (92.31) | 34/35 (97.14) |
| P value | 0.649 | 1.000 | 0.556 |
- Citation: Lin TJ, Lee HC, Lin CL, Wang CK, Chen KY, Wu DC. CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication. World J Clin Cases 2018; 6(12): 514-520
- URL: https://www.wjgnet.com/2307-8960/full/v6/i12/514.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v6.i12.514